NCT01229098View on ClinicalTrials.gov

Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

October 31, 2011

Conditions
Psoriasis Vulgaris
Interventions
DRUG

LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)

LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks

Trial Locations (10)

R3C 0N2

Winnipeg Clinic, Winnipeg

R3C 1R4

Dermadvances Research, Winnipeg

A1B 4S8

Alpha Clinical Research Centre, St. John's

A1C 2H5

Newlab Clinical Research, St. John's

B3H 1Z4

Eastern Canada Cutaneous Research Associates Ltd., Halifax

N5X 2P1

Dermsearch, London

L3P 1A8

Lynderm Research Inc., Markham

L6J 7W5

Institute of Cosmetic and Laser Surgery, Oakville

L1E 3C3

Co-Medica Research Network Inc., Oshawa

L1H 1B9

Oshawa Clinic, Oshawa

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY